NCT00745953View on ClinicalTrials.gov

Regression of Fatty Heart by Valsartan Therapy

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Metabolic SyndromeLipotoxicity
Interventions
DRUG

Valsartan

Valsartan 320mg PO daily for 8 months

DRUG

Hydrochlorothiazide

Hydrochlorothiazide 25mg PO daily for 8 months

Trial Locations (1)

75390

University of Texas Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT00745953 - Regression of Fatty Heart by Valsartan Therapy | Biotech Hunter | Biotech Hunter